TP53 and neoplasm: This demonstrates that, although loss of the tumor suppressor p53 in combination with initiating KrasG12D mutations enhances tumor progression, it does not act to mobilize E-cadherin, correlating with the lack of invasion or metastasis we observed previously in KrasG12D; p53−/− mice (Morton et al., 2010b).